Century Therapeutics (IPSC) Short Interest Ratio & Short Volume

Short interest is the volume of Century Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 1,560,000 shares of IPSC short. 8.20% of Century Therapeutics' shares are currently sold short. Learn More on Century Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IPSC shares currently have a short interest ratio of 13.0. Learn More on Century Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.20% of Century Therapeutics' floating shares are currently sold short.

Century Therapeutics currently has issued a total of 82,850,000 shares. Some of Century Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Century Therapeutics currently has a public float of 19,030,000 shares.

8.20% of Century Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Century Therapeutics: Fennec Pharmaceuticals Inc (7.46%), Opthea Limited (0.19%), Elevation Oncology, Inc. (10.85%), Genfit S.A. (0.18%), INmune Bio, Inc. (14.72%), Kodiak Sciences Inc. (3.76%), Monte Rosa Therapeutics, Inc. (5.98%), Compass Therapeutics, Inc. (1.85%), Cellectis S.A. (0.92%), Adverum Biotechnologies, Inc. (5.85%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling IPSC is an investing strategy that aims to generate trading profit from Century Therapeutics as its price is falling. IPSC shares are trading up $0.26 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Century Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IPSC, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IPSC, twice per month. The most recent reporting period available is May, 15 2024.